1. Home
  2. ELVN vs INVA Comparison

ELVN vs INVA Comparison

Compare ELVN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • INVA
  • Stock Information
  • Founded
  • ELVN 2016
  • INVA 1996
  • Country
  • ELVN United States
  • INVA United States
  • Employees
  • ELVN N/A
  • INVA N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • INVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELVN Health Care
  • INVA Health Care
  • Exchange
  • ELVN Nasdaq
  • INVA Nasdaq
  • Market Cap
  • ELVN 1.2B
  • INVA 1.3B
  • IPO Year
  • ELVN 2020
  • INVA 2004
  • Fundamental
  • Price
  • ELVN $18.50
  • INVA $19.55
  • Analyst Decision
  • ELVN Strong Buy
  • INVA Strong Buy
  • Analyst Count
  • ELVN 5
  • INVA 4
  • Target Price
  • ELVN $41.20
  • INVA $40.25
  • AVG Volume (30 Days)
  • ELVN 459.4K
  • INVA 648.8K
  • Earning Date
  • ELVN 11-12-2025
  • INVA 11-05-2025
  • Dividend Yield
  • ELVN N/A
  • INVA N/A
  • EPS Growth
  • ELVN N/A
  • INVA N/A
  • EPS
  • ELVN N/A
  • INVA 0.53
  • Revenue
  • ELVN N/A
  • INVA $370,229,000.00
  • Revenue This Year
  • ELVN N/A
  • INVA $8.17
  • Revenue Next Year
  • ELVN $25.00
  • INVA $12.06
  • P/E Ratio
  • ELVN N/A
  • INVA $36.56
  • Revenue Growth
  • ELVN N/A
  • INVA 12.02
  • 52 Week Low
  • ELVN $13.30
  • INVA $16.67
  • 52 Week High
  • ELVN $30.03
  • INVA $22.00
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 39.08
  • INVA 43.69
  • Support Level
  • ELVN $18.80
  • INVA $19.11
  • Resistance Level
  • ELVN $21.30
  • INVA $21.11
  • Average True Range (ATR)
  • ELVN 1.08
  • INVA 0.47
  • MACD
  • ELVN -0.13
  • INVA -0.15
  • Stochastic Oscillator
  • ELVN 12.23
  • INVA 21.89

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About INVA Innoviva Inc.

Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Share on Social Networks: